Logo for Viracta Therapeutics Inc

Viracta Therapeutics Investor Relations Material

Latest events

Logo for Viracta Therapeutics Inc

Study Update

Viracta Therapeutics
Logo for Viracta Therapeutics

Study Update

14 Aug, 2024
Logo for Viracta Therapeutics

Q2 2024

14 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Viracta Therapeutics Inc

Access all reports
Viracta Therapeutics Inc. is a precision oncology company focused on developing treatments for virus-associated cancers. The company's leading product candidate, Nana-val, is an all-oral combination therapy comprising its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Beyond Nana-val, Viracta is exploring the "Kick and Kill" approach for other virus-related cancers, aiming to leverage its expertise in oncology to address the needs of patients with virus-associated malignancies globally. Headquartered in Cardiff-by-the-Sea, California, Viracta Therapeutics Inc.'s shares are listed on the Nasdaq.